Gynecology Drugs Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Gynecology Drugs Market with other markets in Healthcare Industry

Gynecology Drugs Market Analysis by Mordor Intelligence

The gynecology drugs market size reached USD 72.97 billion in 2025 and is projected to climb to USD 92.25 billion by 2030 at a 4.8% CAGR, underscoring steady momentum despite supply-chain headwinds and patent expiries. Demographic aging, rapid diagnostic advances, and the FDA’s ongoing reassessment of black-box warnings on hormone therapy together create a supportive regulatory climate that could widen therapeutic adoption. Breakthrough antibody-drug conjugates (ADCs) such as mirvetuximab soravtansine are rewriting standards of care in ovarian cancer, while digital pharmacy models expand contraceptive reach beyond brick-and-mortar outlets. Meanwhile, fem-tech startups secure venture capital to address polycystic ovary syndrome (PCOS) and endometriosis, adding competitive pressure on incumbents with legacy contraceptive portfolios.

Key Report Takeaways

  • By therapeutic class, hormonal therapies captured 68.67% of the gynecology drugs market share in 2024.
  • By indication, contraception contributed 34.53% of the gynecology drugs market size in 2024, while gynecologic oncology is projected to expand at a 6.12% CAGR to 2030.
  • By route of administration, oral products represented 83.12% of the gynecology drugs market size in 2024.
  • By distribution channel, retail pharmacies held 46.23% revenue share in 2024; online pharmacies are forecast to advance at a 5.96% CAGR through 2030.

Segment Analysis

By Therapeutic Class: Portfolio Diversification Accelerates

Hormonal agents generated 68.67% revenue in 2024, sustained by entrenched physician familiarity and decades of efficacy data. Yet non-hormonal entrants grew at a robust 5.45% CAGR, carving niches in menopause and cancer care. Elevated safety profiles attract users who previously avoided hormones, broadening addressable populations. ADCs now create a hybrid sub-class blurring lines between cytotoxics and targeted biologics, pushing parenteral volumes upward. To protect incumbency, leading firms redesign progestins and estrogen analogs with improved metabolic impact. Generics crowd the low-dose contraceptive segment, but premium non-hormonal brands partially offset revenue attrition. 

Forward-looking R&D increasingly incorporates sex-specific endpoints following updated FDA guidance, accelerating bench-to-clinic translation. Venture-backed biotechs exploit this opening with novel neurokinin and GnRH modulators. The gynecology drugs market consequently pivots toward a balanced mix where hormonal stalwarts coexist with innovation-driven non-hormonal franchises.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By Indication: Oncology Commands Premium Pricing

Contraception controlled 34.53% of revenue in 2024, reflecting broad public-health adoption. Nevertheless, oncology posted the fastest 6.12% CAGR as ADCs and targeted inhibitors gained traction. Infertility pharmacotherapy maintains mid-single-digit growth, fueled by rising maternal age and employer-funded IVF benefits. Postmenopausal disorders await broader hormone-safety consensus, but non-hormonal breakthroughs stimulate moderate uptake. PCOS therapies evolve beyond insulin sensitizers toward metabolic agents, expanding indication breadth. Endometriosis saw renewed interest after European endorsement of linzagolix, underscoring global unmet need. 

Osteoporosis biologics achieve incremental gains as reimbursement widens. Infectious-disease antimicrobials remain stable, though topical innovations improve patient adherence. Collectively, the shifting indication mix recalibrates the gynecology drugs market toward higher biological complexity and differentiated value propositions.

By Route of Administration: Precision Therapies Propel Parenteral Growth

Oral dosing dominated with an 83.12% share in 2024, bolstered by daily contraceptives and menopause tablets. Yet parenteral formats advanced at a 5.78% CAGR, leveraging hospital infusion infrastructure for ADCs and long-acting injectables. Intravenous regimens enable controlled pharmacokinetics essential for tumor-targeting payloads, validating investment in cold-chain capacity. Subcutaneous depot injections extend contraceptive coverage up to three months, aligning with adherence-improvement strategies. 

Vaginal gels and rings record steady uptake where localized delivery minimizes systemic exposure. Topical hormonal creams enjoy modest demand for urogenital atrophy, although formulary access varies. Transdermal patches gain momentum among thrombosis-risk patients, offering a bridge between convenience and safety. This evolving route distribution supports manufacturing diversification, strengthening resilience within the gynecology drugs market.

Gynecology Drugs Market: Market Share by Route of Administration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Distribution Channel: Digital Dispensing Gains Momentum

Retail pharmacies accounted for 46.23% of 2024 revenue, underpinned by insurance adjudication workflows and pharmacist counseling. However, online pharmacies accelerated at 5.96% CAGR as telemedicine prescriptions surged post-pandemic. Platform convenience, subscription refills, and discreet delivery resonate with younger demographics, especially for contraception. Hospital pharmacies retain a niche for high-complexity biologics requiring clinician oversight. Emerging omnichannel strategies now integrate digital ordering with same-day pickup at community stores, blurring channel boundaries. 

Regulatory frameworks tighten cybersecurity around reproductive-health data, prompting investment in encryption and identity verification. As API tracking mandates strengthen, distributors deploy blockchain pilots for transparent provenance. These advances collectively modernize supply chains and bolster patient reach, sustaining the gynecology drugs market’s sales velocity.

Geography Analysis

North America generated 32.23% of 2024 sales, leveraging mature reimbursement and rapid FDA approvals to maintain therapeutic leadership. The region’s payer mix encourages swift formulary inclusion of innovations such as elinzanetant, although carboplatin shortages expose manufacturing fragility. Fem-tech investment ecosystems in Boston and San Francisco funnel capital into PCOS and endometriosis pipelines, invigorating competitive churn. Insurer coverage expansions for infertility drugs amplify prescription volumes, further enlarging the gynecology drugs market footprint.

Europe follows with steady uptake across contraceptive and menopause segments, supported by coordinated regulatory pathways. The European Commission’s nod for linzagolix broadened endometriosis options and underscored the continent’s receptivity to non-hormonal mechanisms. Divergent country reimbursement rules necessitate granular market-access strategies, yet centralized safety evaluations speed pan-regional launches. Aging demographics intensify demand for osteoporosis biologics, anchoring long-term growth.

Asia-Pacific is projected to deliver a 6.23% CAGR through 2030, powered by healthcare infrastructure upgrades and rising disposable incomes. Japanese and Australian markets show receptivity to advanced oncology biologics, whereas populous Southeast Asian nations concentrate on affordable contraceptives. Local API production hubs in India and China offer cost advantages yet also present geopolitical risk. Cultural barriers in certain economies moderate hormone-therapy uptake, but urban consumers increasingly prioritize evidence-based gynecological care. Government initiatives that subsidize LARC insertions invigorate segment penetration, expanding the gynecology drugs market across emerging settings.

Gynecology Drugs Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Market structure is moderately fragmented. Bayer, Pfizer, and Johnson & Johnson protect contraceptive franchises via incremental reformulations, while AbbVie and AstraZeneca advance oncology pipelines. Strategic acquisitions characterize 2024-2025; Insud Pharma’s USD 45 million buyout of Agile Therapeutics secured the Twirla patch, and Cosette Pharmaceuticals’ USD 430 million purchase of Mayne Pharma augmented a menopause-focused portfolio. Partnerships with digital pharmacies grow, as incumbents seek direct-to-consumer footholds without disrupting wholesaler ties. Biotechs leverage orphan-drug exclusivities for rare gynecologic cancers, commanding premium reimbursements that offset limited patient populations.

R&D spending gravitates toward non-hormonal menopause solutions and ADC payload optimization. Companies pilot AI-driven trial designs that stratify by hormone status, compressing development cycles. Manufacturing resilience gains board-level visibility after chemotherapeutic shortages; dual-sourcing of platinum APIs and fill-finish redundancy become standard. Sustainability narratives also surface, with firms trialing recyclable blister packs for oral contraceptives.

Competitive pressure intensifies as generics exploit post-2025 patent cliffs. Branded players counter through patient-support programs and loyalty apps that gamify adherence. Yet price ceilings imposed by government insurance in several markets constrain upside. Overall, diversified pipelines and omnichannel engagement strategies remain pivotal for share defense within the gynecology drugs market.

Gynecology Drugs Industry Leaders

  1. Ferring Holding SA

  2. TherapeuticsMD Inc.

  3. AbbVie Inc.

  4. Pfizer Inc.

  5. GSK plc

  6. *Disclaimer: Major Players sorted in no particular order
Gynecology Drugs Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • May 2025: Viatris reported positive Phase III data for the low-dose Xulane LO patch and expects an FDA filing in late 2025
  • March 2025: Final MIRASOL analysis confirmed a 32% mortality reduction with mirvetuximab soravtansine in platinum-resistant ovarian cancer

Table of Contents for Gynecology Drugs Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing preference for long-acting reversible contraceptives (LARCs)
    • 4.2.2 Surging adoption of once-daily non-hormonal menopause therapies
    • 4.2.3 FDA fast-track approvals for antibody-drug conjugates in gynecologic oncology
    • 4.2.4 Rapid expansion of online direct-to-consumer (DTC) fertility drug platforms
    • 4.2.5 Rising investment in fem-tech start-ups targeting PCOS & endometriosis
    • 4.2.6 Country-level reimbursement for osteoporosis biologics
  • 4.3 Market Restraints
    • 4.3.1 Hormone-therapy safety concerns (VTE, breast-cancer risk)
    • 4.3.2 Patent-cliff driven price erosion in oral contraceptives
    • 4.3.3 Socio-cultural barriers to contraception in conservative economies
    • 4.3.4 API supply-chain fragility for niche gynecologic oncology drugs
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter’s Five Forces
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Suppliers
    • 4.7.3 Bargaining Power of Buyers
    • 4.7.4 Threat of Substitute Products
    • 4.7.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts

  • 5.1 By Therapeutic Class (Value)
    • 5.1.1 Hormonal Therapy
    • 5.1.2 Non-Hormonal Therapy
  • 5.2 By Indication (Value)
    • 5.2.1 Contraception
    • 5.2.2 Gynecology Infections
    • 5.2.3 Female Infertility
    • 5.2.4 Postmenopausal Disorders
    • 5.2.5 Polycystic Ovary Syndrome
    • 5.2.6 Osteoporosis
    • 5.2.7 Gynecology Cancer
    • 5.2.8 Endometriosis
    • 5.2.9 Others
  • 5.3 By Route of Administration (Value)
    • 5.3.1 Oral
    • 5.3.2 Parenteral
    • 5.3.3 Topical
    • 5.3.4 Vaginal
    • 5.3.5 Others
  • 5.4 By Distribution Channel (Value)
    • 5.4.1 Retail Pharmacies
    • 5.4.2 Hospital Pharmacies
    • 5.4.3 Online Pharmacies
    • 5.4.4 Others
  • 5.5 By Geography (Value)
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 South America
    • 5.5.4.1 Brazil
    • 5.5.4.2 Argentina
    • 5.5.4.3 Rest of South America
    • 5.5.5 Middle East and Africa
    • 5.5.5.1 GCC
    • 5.5.5.2 South Africa
    • 5.5.5.3 Rest of Middle East and Africa

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Bayer AG
    • 6.3.2 Pfizer Inc.
    • 6.3.3 Merck & Co., Inc.
    • 6.3.4 GSK plc
    • 6.3.5 AbbVie Inc.
    • 6.3.6 AstraZeneca plc
    • 6.3.7 Johnson & Johnson (Janssen)
    • 6.3.8 Eisai Co., Ltd.
    • 6.3.9 F. Hoffmann-La Roche Ltd
    • 6.3.10 Novartis AG
    • 6.3.11 Eli Lilly and Company
    • 6.3.12 Teva Pharmaceutical Industries Ltd.
    • 6.3.13 Viatris Inc.
    • 6.3.14 Amgen Inc.
    • 6.3.15 Sanofi S.A.
    • 6.3.16 Agile Therapeutics, Inc.
    • 6.3.17 Organon & Co.
    • 6.3.18 Cooper Companies, Inc.
    • 6.3.19 Lupin Limited
    • 6.3.20 Cadila Healthcare Ltd. (Zydus Group)

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Gynecology Drugs Market Report Scope

Gynecological drugs are used to treat ailments related to the female reproductive system. A major shift in the lifestyles of women led to a rise in the prevalence of gynecological disorders affecting the functioning of the uterus, ovaries, and appendages.

The gynecology drugs market is segmented by therapeutics, indication, distribution channel, and geography. By therapeutics, the market is segmented as hormonal therapy and non-hormonal therapy). By indication, the market is segmented as gynecology cancers, menopausal disorder, polycystic ovary syndrome, contraception, and other indications. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America).

The report offers the value (USD) for the above segments.

By Therapeutic Class (Value)
Hormonal Therapy
Non-Hormonal Therapy
By Indication (Value)
Contraception
Gynecology Infections
Female Infertility
Postmenopausal Disorders
Polycystic Ovary Syndrome
Osteoporosis
Gynecology Cancer
Endometriosis
Others
By Route of Administration (Value)
Oral
Parenteral
Topical
Vaginal
Others
By Distribution Channel (Value)
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Others
By Geography (Value)
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
India
Japan
South Korea
Australia
Rest of Asia-Pacific
South America Brazil
Argentina
Rest of South America
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
By Therapeutic Class (Value) Hormonal Therapy
Non-Hormonal Therapy
By Indication (Value) Contraception
Gynecology Infections
Female Infertility
Postmenopausal Disorders
Polycystic Ovary Syndrome
Osteoporosis
Gynecology Cancer
Endometriosis
Others
By Route of Administration (Value) Oral
Parenteral
Topical
Vaginal
Others
By Distribution Channel (Value) Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Others
By Geography (Value) North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
India
Japan
South Korea
Australia
Rest of Asia-Pacific
South America Brazil
Argentina
Rest of South America
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

How large is the gynecology drugs market in 2025?

The gynecology drugs market size reached USD 72.97 billion in 2025 and is projected to hit USD 92.25 billion by 2030.

Which therapeutic class generates most revenue?

Hormonal therapies continued to lead, accounting for 68.67% of 2024 sales.

What is the fastest growing regional market?

Asia-Pacific is forecast to expand at a 6.23% CAGR through 2030 as healthcare access improves.

Which indication is expected to grow the quickest?

Gynecologic oncology is projected to rise at a 6.12% CAGR, underpinned by new antibody-drug conjugates.

How are online pharmacies influencing distribution?

Online pharmacies, growing at a 5.96% CAGR, offer telehealth-enabled dispensing that broadens contraceptive and fertility drug access.

What safety issues affect hormone therapy uptake?

Persistent concerns about venous-thromboembolism and breast-cancer risk, coupled with boxed warnings, continue to limit physician prescribing.

Page last updated on:

Gynecology Drugs Market Report Snapshots